Building on these observations, this larger phase 3 trial, with 1-year treatment duration and observation, aims to provide evidence for the effectiveness of C5aR inhibition for the treatment of ANCA-associated vasculitis, with potential to fundamentally change the treatment paradigm of MPA and GPA. This evidence concerns the gene C5AR1 and anti-neutrophil cytoplasmic antibody-associated vasculitis.